Grafix

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Grafix

Quick Facts

Property Description
Active ingredient Mefenamic Acid
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Chemical Subgroup Fenamate (Anthranilic acid derivative)
Primary Forms Tablets, Capsules, Oral Suspension
Origin Synthetic compound

What Type of Medicine is Grafix?

Grafix is a prescription medicine containing the active ingredient Mefenamic Acid. It is categorized as a Non-Steroidal Anti-Inflammatory Drug (NSAID). This classification places the medicine within the category of systemic agents used to manage pain and inflammation.

Mefenamic Acid is a synthetic compound that chemically belongs to the Fenamate chemical subgroup, specifically defined as an Anthranilic acid derivative. This structural distinction provides a therapeutic option within the broad NSAID family. Mefenamic Acid is clinically recognized for its role in modulating the body's pain and inflammatory responses.


Composition, Origin, and Forms of Grafix

The medicinal effect of Grafix is derived solely from the single-ingredient product, Mefenamic Acid, which is manufactured synthetically. For the required systemic treatment, this preparation is administered via the oral route. It is typically provided as various dosage forms, including traditional tablets, capsules, or an oral suspension.


General Purpose and Action

The general purpose of Grafix is to mitigate core symptoms by providing a systemic anti-inflammatory action and a peripheral analgesic effect. This establishes its utility for managing general symptoms of pain, inflammation, and fever (antipyresis).

This effect is achieved primarily through the inhibition of prostaglandin synthesis. Mefenamic Acid functions as a cyclooxygenase (COX) inhibitor, which serves to decrease the production of prostaglandins, the chemical mediators that drive inflammatory and pain responses. NSAIDs like Mefenamic Acid exert an anti-inflammatory and analgesic effect by targeting these specific biological pathways.

What side effects are possible with Grafix?

Safety Profile for Grafix

Grafix is a human cell and tissue-based product (HCT/P) used as a wound cover or barrier. Its safety profile is primarily defined by the risks inherent to all human-derived tissue allografts and general surgical procedures, rather than a list of common drug-like side effects.

Key Risks and Serious Adverse Reactions

The most significant and serious risk associated with any human tissue allograft is the potential for transmission of infectious agents or diseases of known or unknown origin, including bacteria, fungi, or viruses (e.g., HIV or Zika virus), despite mandated donor screening, testing, and aseptic processing. Additionally, the same general medical or surgical complications that apply to any procedure involving tissue transplantation may occur during or following application.

Safety Restrictions and Contraindications

The product is regulated with specific limitations to minimize risk:

  • Active Infection: Grafix is contraindicated and must not be applied to acute or chronic wounds that have an active, untreated infection.
  • Hypersensitivity: It is contraindicated in patients with a known hypersensitivity to the antibiotics used during tissue processing, which may include trace residuals of gentamicin, vancomycin, or Amphotericin B.
  • Single Use Only: The product is intended for single use on a single occasion and must not be re-sterilized.
  • Packaging: Use is strictly prohibited if the sterile package integrity has been compromised.

General Safety Monitoring

Because it is an HCT/P, formal drug frequency classifications (like common or rare) are not typically applied. Healthcare professionals are responsible for adhering to aseptic technique during application and monitoring for any sign of local or systemic complications, including those related to infection or immune reactions, which are possible with any transplanted human tissue.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile of Grafix (Mefenamic Acid) by highlighting a high risk of Central Nervous System (CNS) toxicity. Documented manifestations commonly include seizures (convulsions), confusion, extreme tiredness, and vertigo.

Overdose Manifestations and Complications

Severe exposures are associated with significant systemic risk. Life-threatening outcomes that have been reported include coma, acute renal failure, and gastrointestinal hemorrhage (evidenced by bloody vomit or tarry stools). Since no specific antidote is known for Mefenamic Acid toxicity, the management outlined in regulatory protocols is strictly symptomatic and supportive.

Required Emergency Actions

Immediate medical attention is required for all suspected overdoses. Emergency services must be contacted if the individual collapses, has a seizure, has trouble breathing, or cannot be awakened.

Officially described supportive measures include continuous monitoring of vital functions, gastrointestinal decontamination procedures such as the administration of activated charcoal, and the control of prolonged convulsions. Extended hospital observation for at least 12 hours is required following ingestion.

Therapeutic Uses of Grafix

Grafix is an approved option intended for managing acute symptomatic discomfort associated with common temporary conditions, such as those following mild strains, muscle soreness, and tension headaches. It is intended to provide symptom support during periods of sudden, short-term discomfort, and the relief focuses on temporary symptom management.

It is also a therapeutic approach for individuals managing chronic symptom domains, where ongoing patient support is needed. Grafix can be a potential resource for improving long-term patient well-being and maintaining a baseline quality of life in individuals managing persistent conditions.

By addressing the specific symptoms that may interfere with daily activities, Grafix serves as a tool for functional improvement. By providing symptom support, it may allow patients to maintain better mobility and overall daily functioning. The key indications for use include symptomatic support for inflammation, temporary pain, and generalized body discomfort.


Quick Fact: Relief for Symptomatic Discomfort

Regulatory References

  1. NIH MedlinePlus guidance on approved uses

Eligibility and Restrictions for Use

Grafix (tbo-filgrastim) is a leukocyte growth factor used for certain conditions, and its use is strictly governed by regulatory labeling. Eligibility is determined by age, malignancy type, and specific pre-existing conditions.

Contraindications and Exclusions

Classification Population/Condition
Absolutely Contraindicated Patients with a history of serious allergic reactions to any filgrastim or pegfilgrastim product.
Not Approved/Excluded Patients with myeloid malignancies or myelodysplastic syndrome (MDS).

Eligibility and Conditional Use

  • Age-Related Eligibility: The medicine is indicated for use in adult and pediatric patients 1 month and older. Its safety and effectiveness have not been established in infants younger than 1 month of age. No specific dose adjustment is documented as required for older adults.
  • Condition-Specific Cautions: Use requires close monitoring in patients with sickle cell disorders, as severe and sometimes fatal crises can occur. It must be discontinued if a sickle cell crisis develops. Caution is also advised for patients with suspected glomerulonephritis (kidney disease).
  • Pregnancy and Lactation: Data on use during pregnancy are insufficient to inform risk; use is advised only if the potential benefit justifies the potential risk to the fetus. It is unknown if the drug is present in human milk.

What should I know about interactions with other medicines?

Grafix (Mefenamic Acid) interacts with various medicines and substances, and the official regulatory documents specify several important interaction patterns.

Co-administration with other systemic Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and analgesic doses of Aspirin is generally avoided due to the officially documented potential for serious gastrointestinal events. The interaction profile is structured around two primary regulatory concerns:

  • Increased Bleeding Risk: Grafix is documented to enhance the effects of Oral Anticoagulants (such as Warfarin) and carries an increased risk of gastrointestinal bleeding when combined with SSRIs or Corticosteroids. Additionally, it may interfere with the anti-platelet action of low-dose Aspirin.
  • Altered Drug Exposure: The medicine reduces the renal clearance of substances like Lithium and Methotrexate, a pharmacokinetic interaction that can elevate the plasma concentrations of these co-administered drugs. Combining Grafix with Diuretics or ACE Inhibitors/ARBs is officially noted to reduce the efficacy of these medicines.
  • Substance Interactions: Co-ingestion with Magnesium Hydroxide-containing Antacids significantly increases the rate and extent of Mefenamic Acid absorption. Furthermore, the consumption of Alcohol is noted to increase the risk of gastrointestinal bleeding. Elderly Patients have a documented heightened risk of serious adverse events from these documented interactions.

Mechanism of Action

Grafix is a monoclonal antibody that targets the Receptor Activator of Nuclear Factor kappaB Ligand (RANKL). Binding to the soluble and membrane-bound forms of RANKL prevents its interaction with the Receptor Activator of Nuclear Factor kappaB (RANK) receptor located on the surface of pre-osteoclast and mature osteoclast cells. This physical blockade inhibits the necessary downstream signaling required for the differentiation, activation, and survival of osteoclasts. The resultant disruption of intracellular cascades leads to a reduction in the functional capacity and overall population of osteoclasts. This action mechanistically favors bone formation over bone resorption, resulting in a net decrease in bone tissue breakdown. This modulation of the RANKL-RANK-OPG axis influences the local kinetics of skeletal remodeling processes.

Dosage and Administration Information

Grafix (Mefenamic Acid) is administered via the oral route. The use of this medicine is based on a fixed, short-term regimen constrained by age and duration. The protocol is built on the core principle of using the lowest effective dose for the shortest necessary duration.

Administration Scope and Protocol

Instruction Detail
Route of administration Oral (by mouth), systemic.
Initial Dosing Single starting dose of 500 mg.
Maintenance Dosing 250 mg dose, taken as required.
Frequency The maintenance dose is administered every six hours (q6hr).
Timing in relation to meals Must be taken with food, milk, or a full glass of water to ensure proper administration.
Maximum Duration Short-term use only: not to exceed seven days for acute pain, or two to three days for primary dysmenorrhea.
Age Restriction Not recommended for pediatric patients under 14 years of age.

The protocol involves starting with the initial dose, and subsequent doses are constrained by the six-hour interval and the explicit, short-term duration limit. Dosage adjustments may be necessary for patients with impaired hepatic or renal function.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Grafix

Evidence for Acute Pain Management

Research has widely was studied for its use in managing short-term, acute pain. The evidence landscape for this area relies on short-term Randomized Controlled Trials ( RCTs) and systematic reviews that combine the findings of multiple studies. These trials monitored outcomes related to physical discomfort, tracking how they evolved over defined time intervals. Reports described that outcomes related to physical discomfort were measured within a one-hour interval in some observed populations. The scope of these trials for continuous use is usually limited to about seven days.

Evidence for Primary Dysmenorrhea

Grafix was studied for conditions where symptoms may vary in intensity, specifically primary dysmenorrhea. The evidence here also relies heavily on controlled clinical trials, some of which compared the medication against other standard treatments or a placebo. These trials monitored outcomes capturing phases of heightened symptom activity, tracking them across several consecutive menstrual cycles. Trials data show patterns related to symptomatic changes in measured pain scores during the dosing period of the menstrual cycle.

What Research Gaps and Uncertainty Remain

While research has established patterns observed in the studies for the short-term use of Grafix, there are still areas where certainty remains low. The mathbflong -term effects are not fully established due to limited trial follow-up. This means the research provides context but not individual predictions about sustained outcomes. The comparative evidence is lacking in some areas, and because the evidence quality varies across studies, some findings rely on trials where sample sizes were modest.

Key Studies & References Mefenamic Acid Drug Monograph: Approved Indications and Clinical Pharmacology

Frequently Asked Questions (FAQ)

Common questions about Grafix (FAQ)


Q: What is the difference between Grafix and other similar treatments?

A: Grafix is officially classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). Its specific structure makes it a synthetic compound belonging to the Fenamate chemical subgroup, which chemically distinguishes it from other types of NSAIDs.

Q: How quickly can I expect to see results from Grafix?

A: Official documents note that the active ingredient in Grafix typically reaches its highest concentration in the bloodstream within two to four hours after it's taken by mouth. This time frame indicates when the concentration of the medicine's active ingredient in the bloodstream is generally at its highest.

Q: Can Grafix still be effective if a dose or application is accidentally missed?

A: General medication guidance from official sources indicates that if a dose is missed, patients should typically avoid taking a double dose to try and catch up. The guidance is usually to continue with the next regularly scheduled dose.

Q: What are the most common minor side effects reported with Grafix?

A: The most frequently reported minor side effects may include symptoms like heartburn, stomach pain, gas, nausea, vomiting, diarrhea, or constipation. Some people may also experience dizziness. This information is derived from official drug labels and regulatory documents.

Q: Do the side effects of Grafix get worse over time or after repeated use?

A: Regulatory warnings indicate that the risk of certain serious side effects, specifically those related to the heart and blood vessels (cardiovascular thrombotic events), may increase with the duration of use. This is consistent with the regulatory constraints that limit the use of this medicine to short-term therapy.

Q: What is the likelihood of a serious allergic reaction to Grafix?

A: The product is contraindicated if a patient has a history of allergic-type reactions to aspirin or other NSAIDs. Serious and sometimes life-threatening allergic reactions, known as anaphylaxis, have been reported with NSAIDs, and this information is provided to highlight the importance of adhering to the contraindication.

Q: How long after the initial use does the full effect of Grafix typically appear?

A: The time required for the active ingredient to reach its peak concentration in the blood is reported in official product information as being typically two to four hours after the first oral dose. This period is reported as the time when the active ingredient's concentration is highest following the initial dose.

Q: Is Grafix a treatment that requires long-term or indefinite use?

A: According to official product information, no. Grafix is indicated only for the relief of short-term, acute pain and its use is constrained to the relief of short-term, acute pain, as specified in the regulatory indications.

Q: Why is Grafix sometimes used after surgery?

A: The medicine is officially indicated for the relief of mild to moderate pain. This utility means its use can encompass the management of temporary pain that is commonly experienced by patients following certain surgical procedures.

Q: What is the general success rate described in the research for Grafix?

A: Clinical studies have examined the medicine’s efficacy by observing specific outcomes related to physical discomfort for acute pain. Research has reported patterns related to symptomatic changes in measured pain scores for conditions like primary dysmenorrhea during the short periods examined in the trials.

Q: Does using Grafix affect my ability to drive or operate machinery?

A: Because side effects such as dizziness, drowsiness, or blurred vision, can occur, official patient information generally notes that activities requiring alertness, such as driving or operating machinery, should be avoided if these side effects occur.

Q: Is there a maximum number of times Grafix can be applied safely?

A: While regulatory labeling does not specify a maximum number of total courses over a lifetime, it documents that the duration of each individual treatment course is constrained to not exceed seven days for acute pain or two to three days for menstrual pain.

Q: Does Grafix interact with common pain relievers like ibuprofen or acetaminophen?

A: Official documents advise that Grafix should not be used with other NSAIDs, which includes ibuprofen, due to the increased risk of certain side effects without increased benefit. However, the regulatory label does not specifically cite an interaction with acetaminophen.

Q: Are there any specific activities to limit while undergoing treatment with Grafix?

A: Official instructions note that patients should limit or avoid alcohol consumption while taking this medicine. This is because combining alcohol with Grafix is associated with a documented increase in the risk of gastrointestinal bleeding.

Q: Does the age of the patient influence how well Grafix works?

A: The medicine is not indicated for use in pediatric patients under 14 years of age because official sources state that safety and effectiveness in that younger age group have not been established through clinical research.

Q: What are the known risks of using Grafix in the elderly population?

A: Official product information notes that elderly patients have a greater documented risk for serious gastrointestinal adverse events compared to younger adults. Official documentation notes that caution should be exercised because of the potential for age-related decline in kidney function.

Q: How do I know if the Grafix I received is the correct type or size?

A: The medicine is available in specific dosage forms, such as tablets, capsules, or an oral suspension. The product’s official label must contain the active ingredient Mefenamic Acid, which can be verified against the prescribing information.

Q: Does Grafix have any known effects on fertility or reproductive health?

A: Official product information advises that NSAIDs, including Grafix, may be associated with a reversible delay in ovulation in females of reproductive potential who are trying to become pregnant.

Q: Are there any known interactions between Grafix and common supplements like vitamins or herbal remedies?

A: The official interaction profile specifies that Magnesium Hydroxide-containing Antacids increase how much of the medicine is absorbed. The regulatory label does not explicitly detail interactions with common vitamins or many other herbal remedies.

Q: Are there any specific foods or drinks that should be avoided while using Grafix?

A: Official instructions note that consuming alcohol is associated with an increased risk of gastrointestinal bleeding and should be limited or avoided. Conversely, the medicine is required to be taken with food, milk, or a full glass of water for proper administration.

Q: Can Grafix be used by pregnant or breastfeeding women?

A: Official warnings state that use of this medicine is contraindicated starting at 30 weeks of gestation due to the documented risk to the fetus. The labeling for earlier use advises that the potential benefit should justify the potential risk to the fetus. Official information notes that it is currently unknown if the medicine is present in human milk.

Q: What is the expected duration of treatment with Grafix?

A: Grafix is indicated for short-term use only. Official indications constrain the treatment course to typically not exceed seven days for acute pain and two to three days for the treatment of primary dysmenorrhea.

How should Grafix be stored and disposed of?

Storage and Handling Requirements

Grafix (Mefenamic Acid) must be stored at Room Temperature, defined as 20 C to 25 C. The medicine should be kept away from excess heat, moisture, and direct light; it must not be frozen. It is essential to keep the medication in the container it came in and ensure the container is tightly closed.

Child Safety and Stability

The product must always be stored out of the sight and reach of children, and safety caps must remain locked. Do not use this medicine after the expiry date on the packaging, and do not keep medicine that is outdated or no longer needed.

Disposal Instructions

Expired or unused Grafix should not be disposed of in household trash or via wastewater. Patients should consult a pharmacist or doctor for instructions on how to properly discard the product in accordance with local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Grafix found in:

A-Z Index: